Peapod Lane Capital LLC Makes New $577,000 Investment in Whitehawk Therapeutics, Inc. $WHWK

Peapod Lane Capital LLC purchased a new position in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 303,585 shares of the company’s stock, valued at approximately $577,000.

Separately, Vanguard Group Inc. acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter valued at about $2,552,000. Institutional investors own 52.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on WHWK shares. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Monday, December 29th. Oppenheimer initiated coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price target on the stock. Wall Street Zen downgraded shares of Whitehawk Therapeutics to a “strong sell” rating in a report on Saturday, November 1st. Finally, JonesTrading initiated coverage on shares of Whitehawk Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.50.

Whitehawk Therapeutics Stock Performance

WHWK opened at $3.05 on Monday. The business has a 50 day moving average of $2.71 and a 200-day moving average of $2.29. The stock has a market capitalization of $143.75 million, a price-to-earnings ratio of 21.79 and a beta of 0.59. Whitehawk Therapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $3.77.

Whitehawk Therapeutics Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.